Press Release

The right treatment at the right time to the right patient

In an ever-changing health economy, with tightening regulations and a focus on cost effectiveness, a thorough understanding of the healthcare environment and a well-considered market access strategy are vital for pharma to effectively communicate their service offering.

This ensures products and services are delivered to the right people and in the right way, at the right time. Most importantly, it allows patients struggling with conditions to access treatments and medicines capable of improving their health.

Bridging the gap between the NHS and pharmaceutical companies

Interface Clinical Services, an IQVIA business, deliver clinical review services to primary care through a nationwide team of clinical pharmacists. It enables the pharmaceutical industry to effectively engage with the NHS and the wider healthcare environment. It also helps:

• Identify gaps in service provision and specific treatment needs within a patient population
• Manage high-risk patients, including recommending patients for medicinal and non-medicinal interventions where appropriate
• Provide the NHS with increased clinical resources
• Focus resource and maximise the strategic benefit
• Support product launch and growth strategies for pharmaceutical companies

Case study: Improving high-risk asthmatic patients’ treatments and outcomes

The Interface Clinical Services team delivered a clinical review of high-risk asthmatic patients across a Health Care Partnership spanning 52 medical practices. 13 pharmacists supported over 18,000 NHS patients over 4 months. Patients benefited from 5,488 medicinal interventions, including 1,582 patients who were initiated on a treatment. 59% of patients invited, attended pharmacist-led clinics and received personalised guidance and education.

In a COVID-19 environment, this clinical review enabled the Health Care Partnership to:

• Provide additional support to patients with respiratory conditions and ensure they continue to receive the care they need
• Ensure that asthmatic patients were supported to achieve optimal management
• Protect vulnerable patients, ensure continuity of care and prevent non-COVID related, unplanned primary and secondary care encounters